Oculogica secured FDA 510k clearance for SNAP, moving its eye-tracking technology closer to the point of initial concussion assessment. The portable infrared tool measures eye movements during a short visual task and combines them with self-reported symptom severity. Its 15-to-25 age label positions high school and college sports as the clearest early market. SNAP extends a product line that began with EyeBOX, cleared via De Novo in 2018.